SGLT2 Inhibitors Protect Against Heart Failure, Kidney Disease

The metabolic effects of these anti-diabetes medications reduce risks associated with both heart failure and kidney disease, even in individuals without diabetes

By
estaff
-
Published:
0
© Westend61 | Getty Images SGLT2 inhibitors are so effective at lowering the rates of heart failure hospitalization and cardiac death and protecting the kidneys that they are considered an essential medication for patients with symptomatic heart failure.

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are a new class of medications for individuals with type 2 diabetes (T2D). While their blood-sugar-lowering ability is only mild-to-moderate, other properties set them apart: The protection they provide to individuals with heart failure (HF) and diabetic kidney disease is nothing short of remarkable.

To continue reading this article or issue you must be a paid subscriber. Sign in
Subscribe

Subscribe to Heart Advisor

Get the next year of Heart Advisor for just $20. And access all of our online content - over 2,000 articles - free of charge.
Subscribe today and save 38%. It's like getting 5 months FREE!
Already Subscribed?
Click Here to Sign In | Forgot your password? | Activate Web Access

RELATED ARTICLESMORE FROM AUTHOR